XML 17 R7.htm IDEA: XBRL DOCUMENT v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Operating activities:    
Net income (loss) $ 90,884 $ (10,812)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 3,073 2,363
Amortization of patents 470 443
Amortization of premium on investments, net (2,433) 1,192
Amortization of debt issuance costs 474 441
Amortization of convertible senior notes discount 8,726 8,083
Stock-based compensation expense 45,505 28,451
Non-cash losses related to patents, licensing and property, plant and equipment 14 175
Provision for deferred income taxes 13,549 0
Changes in operating assets and liabilities:    
Contracts receivable 4,908 26,097
Inventories (2,475) 922
Other current and long-term assets 1,802 11,422
Accounts payable (17,191) (13,144)
Accrued compensation (13,004) (12,985)
Accrued liabilities and deferred rent 13,756 (1,695)
Deferred contract revenue (40,353) (27,788)
Net cash provided by operating activities 107,705 13,165
Investing activities:    
Purchases of short-term investments (492,781) (91,157)
Proceeds from the sale of short-term investments 426,868 173,724
Purchases of property, plant and equipment (3,229) (2,343)
Acquisition of licenses and other assets, net (1,032) (738)
Net cash provided by (used in) investing activities (70,174) 79,486
Financing activities:    
Proceeds from equity awards 67,057 5,675
Payments of tax withholdings related to vesting of employee stock awards (7,597) 0
Offering costs paid 0 (451)
Net cash provided by financing activities 59,460 5,224
Net increase in cash and cash equivalents 96,991 97,875
Cash and cash equivalents at beginning of period 278,820 129,630
Cash and cash equivalents at end of period 375,811 227,505
Supplemental disclosures of cash flow information:    
Interest paid 667 644
Supplemental disclosures of non-cash investing and financing activities:    
Right-of-use assets obtained in exchange for lease obligations 13,557 0
Amounts accrued for capital and patent expenditures $ 1,864 $ 2,091